MC
IMRX icon

Moors & Cabot’s Immuneering IMRX Stock Holding History

Moors & Cabot’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.9K Hold
10,000
– – ﹤0.01% 946
2026
Q1 		$52.7K Hold
10,000
– – ﹤0.01% 912
2025
Q4 		$65.8K Sell
10,000
-1,000
-9% -$6.42K ﹤0.01% 901
2025
Q3 		$77K Buy
+11,000
New +$57.1K ﹤0.01% 886

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Moors & Cabot's IMRX Position: Q2 2026 in Review

Moors & Cabot held its Immuneering (IMRX) position steady in Q2 2026 at 10,000 shares worth $49.9K. The position accounts for ﹤0.01% of the portfolio, ranked #946.

Moors & Cabot first reported a position in IMRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $77K in Q3 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Moors & Cabot held 10,000 shares of Immuneering worth $49.9K as of Q2 2026.
  • Moors & Cabot left its Immuneering share count unchanged in Q2 2026.
  • Immuneering made up ﹤0.01% of Moors & Cabot's portfolio in Q2 2026, its #946 holding.
  • Moors & Cabot first reported a position in Immuneering in Q3 2025 and has held it in 4 quarters since.
  • Moors & Cabot's Immuneering position peaked at $77K in Q3 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.